Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347/CH5183284, a Selective FGFR 1,2,3 Inhibitor

LAUSANNE, Switzerland, April 15, 2016 /PRNewswire/ --

Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) taking place in New Orleans, by Debiopharm and Chugai Pharmaceutical Co., Ltd.

Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying FGFR 1, 2, or 3 genetic alterations. Debiopharm is investigating patient selection criteria with the aim of enabling personalized treatments with Debio 1347/CH5183284 associated with a companion diagnostic.

'We are very pleased to present this latest set of scientific data relating to our FGFR inhibitor, which further reinforces Debiopharm's commitment to the advancement of personalized therapies which have the potential to improve and extend the lives of individuals living with cancer,' said Dr Nigel McCracken, Vice President, Translational Medicine, Debiopharm International SA.

AACR 2016 Abstract 

Title Date AND Time Ndegree(s)
FGFR selective inhibitor Debio 1347 induces tumor
regression in FGFR2-altered gastric cancer PDX
Wed, April 20
Presented by Debiopharm International SA 7:30 - 11:00 4784
ERK signal suppression and sensitivity to
CH5183284/Debio 1347, a selective FGFR inhibitor
Presented by Chugai Pharmaceutical Co., Ltd. Kamakura Tue, April 19
Japan 8:00 - 12:00 3028

About Debiopharm International SA 

Debiopharm Group(TM) is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit

We are on Twitter. Follow us @DebiopharmNews at

Debiopharm International SA Contact 
Christelle Tur 
Communication Coordinator 
Tel: +41(0)21-321-01-11 
Additional Media Contacts 
In London 
Chiara Valsangiacomo 
Tel: +44(0)20-7379-5151 
Russo Partners, LLC 
Lena Evans 
Assistant Vice President 
Tel: +1-212-845-4262 


Debiopharm Group

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234